Downloadable Slides

Share

Program Content

Activities

BRCAAway Phase II Trial
BRCAAway: Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in HRR-Mutant Metastatic CRPC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2024

KEYNOTE-564
KEYNOTE-564: Updated Analysis of a Phase III Trial of Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Clear Cell Renal Cell Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

Erdafitinib and EV Sequencing in aUC
Erdafitinib and Enfortumab Vedotin Sequencing in Patients With FGFR2/3-Altered aUC: UNITE Database Retrospective Analysis
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 01, 2024

PemCab in aUC
PemCab: Phase II Study of First-line Cabozantinib + Pembrolizumab for Cisplatin- or Platinum-Ineligible Patients With aUC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

EV-302/KEYNOTE-A39
Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 01, 2024

A031501 AMBASSADOR
A031501 AMBASSADOR: Phase III Trial of Pembrolizumab vs Observation as Adjuvant Therapy for High-Risk Muscle-Invasive Urothelial Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2024

CONTACT-02
CONTACT-02: Cabozantinib + Atezolizumab vs Second Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 31, 2024

Provided by

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

AstraZeneca

Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC